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Abstract
Introduction: The attainment of remission has become an important end point for clinical trials in juvenile
idiopathic arthritis (JIA), although we do not yet have a full understanding of what remission is at the cell and
molecular level.
Methods: Two independent cohorts of patients with JIA and healthy child controls were studied. RNA was
prepared separately from peripheral blood mononuclear cells (PBMC) and granulocytes to identify differentially
expressed genes using whole genome microarrays. Expression profiling results for selected genes were confirmed
by quantitative, real-time polymerase chain reaction (RT-PCR).
Results: We found that remission in JIA induced by either methotrexate (MTX) or MTX plus a TNF inhibitor
(etanercept, Et) (MTX + Et) is characterized by numerous differences in gene expression in peripheral blood
mononuclear cells and in granulocytes compared with healthy control children; that is, remission is not a
restoration of immunologic normalcy. Network analysis of the differentially expressed genes demonstrated that the
steroid hormone receptor superfamily member hepatocyte nuclear factor 4 alpha (HNF4a) is a hub in several of
the gene networks that distinguished children with arthritis from controls. Confocal microscopy revealed that
HNF4a is present in both T lymphocytes and granulocytes, suggesting a previously unsuspected role for this
transcription factor in regulating leukocyte function and therapeutic response in JIA.
Conclusions: These findings provide a framework from which to understand therapeutic response in JIA and,
furthermore, may be used to develop strategies to increase the frequency with which remission is achieved in
adult forms of rheumatoid arthritis.
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Introduction
The advent of biological therapies for chronic forms of
arthritis has been accompanied by the hopes that: (1)
therapies can be increasingly tailored to specific pathogenic
pathways, decreasing unwanted side effects; and (2) by use
of more targeted therapies, patients will experience more
sustained periods of disease quiescence and, therefore,
functional and subjective well-being. In juvenile idiopathic
arthritis (JIA), the most common form of chronic arthritis
in children, achieving the second of these objectives
appears to be very near [1].
JIA is a term used to denote a heterogeneous group of
childhood illnesses characterized by chronic inflamma-
tion and hypertrophy of synovial membranes. Distinct
phenotypes are recognized based on disease presentation,
clinical course, and specific biomarkers, for example, IgM
rheumatoid factor [2]. However, even within carefully
specified disease subtypes, considerable heterogeneity
exists, especially with respect to response to therapy and
overall outcome [3]. The biology underlying these differ-
ences is poorly understood, and obtaining a molecular
understanding of phenotypic and therapeutic response
differences is an important step toward developing indivi-
dualized therapies for this family of diseases and their
cognate conditions in adults.
A major advance in pediatric rheumatology has been
the recognition that treatment response can be staged
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based on consensus criteria developed by an interna-
tional panel [4], and that these stages have biological
validity that can be characterized at the molecular level
by gene transcriptional profiling [5-7]. Wallace et al. [4]
defined these specific states as: active disease (AD), inac-
tive disease (ID), clinical remission on medication (CRM),
and clinical remission (CR). While true remission (CR)
appears to be difficult to achieve (in the Wallace study [7],
only 5% of children with the multiple-joint, polyarticular
form of JIA achieved remission within 5 years of diagno-
sis), sustained periods of disease control (CRM) have
become a reality and the target end point for childhood
arthritis clinical trials. However, although achieving CRM
has become commonplace in pediatric rheumatology clini-
cal care, preliminary studies have suggested that the CRM
biological state is not a return to normal, but, rather, a
homeostatic state where pro-inflammatory disease net-
works are counterbalanced by the emergence of anti-
inflammatory networks [6]. Indeed, peripheral blood gene
expression abnormalities persist even in children who
have been disease-free and off medication for a year or
more [5,6].
Now that remission (or at least CRM) has become both
the gold standard for clinical care and the end point for
clinical trials for children, it is critical that we understand
it at the molecular/biological level. One complication in
doing so is that, while approximately 35 to 50% of children
with JIA will experience CRM with the use of methotrex-
ate (MTX) (usually in combination with nonsteroidal anti-
inflammatory drugs +/- corticosteroids, used systemically
or via joint injection), others will attain this state only after
a biological agent, most commonly a TNF inhibitor, is
added to methotrexate and the other agents [8]. However,
whether the state of remission induced by MTX is, at the
molecular level, identical to remission induced by the
addition of a TNF inhibitor remains unknown, even
though the remission phenotype is identical in each case.
Answering this question is critical to our understanding of
both the biology of response to therapy in JIA and toward
our understanding the disease process itself. Furthermore,
while there may be fundamental differences in the biology
of response in adults compared to children and between
the different disease entities in which anti-TNF therapies
are used, the frequency with which remission (as defined
here) can be achieved in children provides an excellent
opportunity to understand mechanisms of response in
such a way that these therapies might be manipulated in
adults or in other diseases to achieve the same ends. Thus,
understanding remission at the molecular level in this spe-
cific disease can be expected to have a useful impact on
the multiple other chronic forms of arthritis in which
immunosuppressive and anti-TNF therapies are used.
In this study, we used gene expression profiling to
compare two groups of children with JIA who had
achieved remission (CRM) to examine the medication-
specific effects on gene transcriptional profiles.
Materials and methods
Patients and controls
This study was approved by the Oklahoma University
Health Sciences Center (OUHSC) Institutional Review
Board, and informed consent was obtained from all
patients, or their parent/guardian, prior to the initiation
of the study. We studied two independent cohorts of
patients. One cohort was designated the training cohort,
and the second, termed the testing cohort, was used to
corroborate the results from the training cohort using
quantitative, real-time PCR (qRT-PCR).
Children with polyarticular onset, rheumatoid factor
(RF)-negative JIA were recruited from the OU Chil-
dren’s Physicians’ rheumatology clinics and fit criteria
for this subtype as specified by the International League
of Associations for Rheumatology (ILAR) [9]. All chil-
dren were on treatment at the time they were studied,
and all fit criteria for CRM as defined by Wallace and
colleagues [7]. That is, these children had all reached
the ID state (normal physical examinations, absence of
morning stiffness, and normal complete blood counts
and erythrocyte sedimentation rates on laboratory moni-
toring studies) and, to fit criteria for CRM status, had
maintained the ID state for 6 continuous months. The
patients were followed every 2 to 3 months following
their achieving ID, and CRM state samples were taken 6
to 8 months following the achievement of ID status. In
the training cohort (for microarray), 14 children (ages
8.9 ± 3.1 years; seven females and seven males) achieved
CRM with the use of MTX alone, 7 to 48 months after
starting therapy. The patient comparison group in this
cohort consisted of 14 other children with polyarticular
JIA (ages 8.9 ± 4.2 years; 13 females and one male) who
achieved CRM only after the addition of the TNF inhibi-
tor, etanercept (Et), 11 to 48 months after the initiation
of therapy. Both of these groups were compared to a
group of 15 healthy children (ages 11.5 ± 2.6 years;
seven female and eight male) recruited from the OU
Children’s Physicians’ General Pediatrics clinic (Table 1).
A separate testing patient cohort of children with JIA
was used to validate results from the first patient cohort.
Eight of these children (ages 9.4 ± 4.7 years; eight females)
achieved CRM with the use of MTX alone, 10 to 27
months from the initiation of therapy, and an additional
eight children with polyarticular JIA (age 9.6 ± 4.5 years;
eight females) achieved CRM only after the addition of Et,
10 to 26 months after the initiation of therapy. Eight
healthy children (age 11.1 ± 2.8 years; four females and
four males) were used as an independent comparison
group to the testing cohort. Patient groups and character-
istics are summarized in Table 1. All patients were treated
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with naproxen, 10 mg/kg/dose, as an adjunct to their pri-
mary drugs (that is, MTX +/- Et).
Cell isolation
Whole blood was drawn into 10 mL citrated Cell Prepara-
tion Tubes (Becton Dickinson, Franklin Lakes, NJ, USA).
Cell separation procedures were started within one hour
from the time the specimens were drawn. Peripheral
blood mononuclear cells (PBMC) were separated from
granulocytes and red blood cells by density-gradient cen-
trifugation. Red cells were removed from granulocytes by
hypotonic lysis, and PBMC and granulocytes were then
immediately placed in TRIzol™ reagent (Invitrogen, Carls-
bad, CA, USA) and stored at -80°C.
RNA isolation, labeling and gene expression profiling
Total RNA was extracted using TRIzol™ reagent accord-
ing to the manufacturer’s directions. RNA was further
purified using a RNeasy MiniElute cleanup kit including a
DNase digest according to the manufacturer’s instructions
(Qiagen, Valencia, CA, USA). RNA was quantified spec-
trophotometrically (Nanodrop, Thermo Fisher Scientific,
Wilmington, DE, USA) and assessed for quality by capil-
lary gel electrophoresis (Agilent 2100 Bioanalyzer; Agilent
Technologies, Inc., Palo Alto, CA, USA). For the training
cohort, sufficient amounts of high quality RNA for use in
microarrays were obtained from 43 PBMC samples
obtained from 14 JIA patients treated with MTX + Et,
14 JIA patients treated with MTX alone, and 15 healthy
control children. From granulocytes, a sufficient amount
of high quality RNA was obtained from 12 JIA patients
treated with MTX + Et, 10 JIA patients treated with MTX
alone, and 13 healthy control children. RNA samples were
processed using GeneChip 3’ IVT Express kit and hybri-
dized to human U133 Plus 2.0 GeneChip™ microarrays
according to the manufacturer’s protocol (Affymetrix,
Santa Clara, CA, USA). GeneChips™ were washed and
stained using an Affymetrix automated GeneChip™ 450
fluidics station and scanned with an Affymetrix 3000 7G
scanner. All gene expression data has been made available
Table 1 Demographic characteristics of study participants
Training group
Response to methotrexate Response to methotrexate + etanercept Healthy control
Patients Age Time to CRM Patients Age Time to CRM Control Age
(month) (month)
1 9 7 1 13 20 1 16
2 16 8 2 3 24 2 18
3* 11 10 3 3 48 3 9
4 7 14 4 6 8 4 11
5 11 12 5 4 18 5 10
6* 6 15 6 5 42 6 11
7 7 32 7 14 15 7 10
8* 11 13 8 9 25 8 10
9 7 36 9 10 30 9 11
10 4 46 10 15 25 10 13
11 11 8 11 11 20 11 13
12 7 15 12 12 24 12 10
13 11 48 13 12 24 13 12
14* 6 9 14 7 11 14 12
Testing group
Response to methotrexate Response to methotrexate + etanercept Healthy control
Patients Age Time to CRM Patients Age Time to CRM Control Age
(month) (month)
1 12 27 1 9 24 1 12
2 5 12 2 17 10 2 15
3 12 11 3 6 17 3 8
4 14 11 4 7 26 4 9
5 16 11 5 12 26 5 8
6 5 13 6 5 18 6 11
7 4 10 7 6 24 7 15
8 7 17 8 15 16 8 11
*RNA from granulocytes was insufficient for microarray analysis. CRM, clinical remission on medication.
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publically via the Gene Expression Omnibus (accession
GSE41831).
Statistical analysis and network modeling
CEL files were generated from scanned images using
GeneChip™ Operating Software (GCOS, Affymetrix, ver-
sion 1.3.0.037). Signal intensities were generated using
JustRMA software (BRB-Array Tools). A log base 2
transformation was applied before the data were quan-
tile normalized. Signal intensities were filtered using a
log intensity variation (BRB-Array Tools) to obtain
probes with the 25% highest variance across the arrays
(13,668 probes) for further evaluation. Samples were
divided into three groups (controls, patients treated with
MTX + Et, and patients treated with MTX alone) and
gene expression differences were separately evaluated in
each patient group relative to controls. Differences
between groups were considered statistically significant
using a two-sample t test with univariate random var-
iance model if the P value was ≤0.001 (BRB Array
Tools, version 3.8.0 stable release). Statistically signifi-
cant differentially expressed genes were filtered to
obtain those with a minimal 1.3-fold change between
groups and a mean expression level above background
in at least one group. Annotations for probes were
obtained from Affymetrix and were further supplemen-
ted by SOURCE [10]. These gene annotations were
compared with the Gene Ontology (GO) database [11]
to identify overrepresented terms using the R package
GO available from Bioconductor within BRB-Array
Tools [12]. A minimum of five observations in a GO
class and parent class plus a minimum ratio of 2 for the
observed vs. expected numbers were required for further
consideration.
Interactions among differentially expressed genes in
PBMC and granulocytes were analyzed using Ingenuity
Pathway Analysis (IPA) software (Ingenuity Systems, Inc,
Redwood City, CA, USA). Differentially expressed genes
were mapped onto a global molecular network developed
from information contained in the Ingenuity Pathways
Knowledge Base.
Gene expression validation by quantitative real-time
RT-PCR
Total RNA (described above) was reverse transcribed
with iScript™ cDNA synthesis kit according to the direc-
tions of the manufacturer (Bio-Rad, Hercules, CA, USA).
Real-time RT-PCR was performed using SYBR Green
reagents on an ABI Prism 7000 (for the training group;
Applied Biosystems, Foster City, CA, USA) or a StepOne
Plus (for the testing group; Applied Biosystems, Foster
City, CA, USA). The temperature profile consisted of an
initial 95°C step for 10 min, followed by 40 cycles of 95°C
for 15 sec, 60°C for 1 min, and then a final melting curve
analysis with a ramp from 60°C to 95°C over 20 min.
Gene-specific amplification was confirmed by a single
peak in the ABI Dissociation Curve software. Average
threshold cycle (Ct) values for GAPDH (run in parallel
reactions to the genes of interest) were used to normalize
average Ct values of the gene of interest. These values
were used to calculate averages for each group (healthy
control or patient subsets), and the relative ΔCt was used
to calculate fold-change values between the groups [5].
The nucleotide sequences of the primers are listed in
Table 2.
Table 2 Primers used for quantitative real-time PCR
validation.
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Confocal microscopy for hepatocyte nuclear factor
4 alpha (HNF4a)
Human PBMC and granulocytes, isolated as described
above, were adhered to poly-L-lysine-coated coverslips
(Sigma-Aldrich, St. Louis, MO, USA) for 30 min at room
temperature. Cells were fixed with 3% formaldehyde in
PBS for 10 min at room temperature. After fixation, cells
were treated with 0.25% Triton X-100 in PBS for 15 min.
Slides were washed twice in PBS and blocked with block-
ing buffer (1% BSA, 1% donkey serum, 0.3M glycine in
PBS containing 0.05% Tween 20) for 30 min. PBMC were
incubated with rabbit anti-human HNF4a mAb (Cell Sig-
naling Technology, Inc., Danvers, MA, USA) plus mouse
anti-human CD4 mAb (Biolegend, San Diego, CA, USA),
or rabbit anti-human HNF4a mAb plus mouse anti-
human CD8 mAb (Biolegend, San Diego, CA, USA), and
granulocytes were incubated with rabbit anti-human
HNF4a mAb plus FITC-conjugated mouse anti-human
CD66b mAb (BD Biosciences, San Jose, CA, USA), over-
night at 4°C. After being washed with PBS, cells were incu-
bated with Alexa Fluor 568- or 647-conjugated secondary
antibody for 45 min at room temperature. After three
rinses in PBS, the coverslips were mounted onto glass
slides using ProLong Gold antifade reagent (Invitrogen,
Carlsbad, CA, USA) with 4’,6-diamidino-2-phenylindole
(Invitrogen, Carlsbad, CA, USA). Fluorescent confocal
laser scanning microscopy was conducted with a Leica
SP2 MP laser scanning confocal microscope using the
Leica confocal software LCS Lite (Leica Microsystems HD
GmbH, Mannheim, Baden-Württemberg, Germany).
Results
Our primary aim in this study was to determine whether
the CRM state as achieved in a typical clinical setting
results in a return to normal immune homeostasis in
peripheral blood leukocytes. Preliminary studies from
our research group [5,6] indicated that this was not
likely, and this study, performed on a larger group of
patients with independent corroboration in a second
group of patients, was designed to answer that question
in a definitive way and elucidate differences at the mole-
cular level. To do this, we first compared each of the
CRM groups (that is, MTX or MTX + Et) to healthy
control children.
In both PBMC and in granulocytes, there were differ-
ences between children who achieved remission on MTX
compared with those who achieved remission on MTX +
Et relative to healthy control children. That is, although
remission (CRM) is a distinct biological state, and pheno-
typically is indistinguishable among the groups, there
were still differences in patterns of gene expression
between and among the groups. For both cell types, hier-
archical clustering of samples from the three groups (that
is, healthy controls, children who had achieved remission
on MTX, and children who had achieved remission on
MTX + Et) revealed two clusters, each containing a simi-
lar proportion of samples from children in remission on
MTX and healthy control children, while all but one of
the samples from children who achieved remission on
MTX + Et were grouped in one cluster. A 3 × 2 contin-
gency table of these distributions revealed a nonrandom
distribution of samples in both cell types (Table 3;
PBMC: X2 = 9.86, P < 0.007; granulocytes: X2 = 11.5, P <
0.003). These results suggest that combined treatment
with MTX + Et produced distinct gene expression
responses that are distinct and more biologically focused
at the gene expression level from the more heteroge-
neous responses detected among the MTX-treated
Table 3 Summary of hierarchical cluster analysis in PBMC
and granulocytes from healthy control and in PBMC and
granulocytes from children with JIA who achieved
remission with methotrexate or methotrexate and
etanercept
Cells Group Left Cluster Right Cluster
PBMC MTX + Et 1 14
MTX 8 6
Controls 8 7
Granulocytes MTX + Et 13 1
MTX 3 7
Controls 5 7
ET, etanercept; JIA, juvenile idiopathic arthritis; MTX,
methotrexate; PBMC, peripheral blood mononuclear cells.





















1Forward primer direction (F), reverse primer direction (R).
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patients, consistent with the idea that Et represents a
more targeted therapy.
Differences in PBMC gene expression profiles
Gene expression differences were detected in 67 genes
represented by 75 probes when PBMC from JIA patients
who achieved remission using MTX alone were compared
to healthy controls. Twenty-two of these genes showed
higher levels of expression and 45 showed lower levels in
patient compared with control samples (Table S1 in Addi-
tional file 1). Thus, MTX appears to act not merely by
suppressing pro-inflammatory genes, but by a re-ordering
of specific transcript levels. Not surprisingly, functional
associations among the differentially expressed genes
included genes whose products are active in cell-mediated
immunity. This included decreased expression of signal
transducer and activator of transcription 1 (STAT1),
which plays an important role mediating the effects of
interferon gamma and in TH17 cell differentiation.
STAT1 is activated by IL-6, an important cytokine in the
pathogenesis of JIA [13] and IL-6 is known to be modu-
lated by methotrexate [14,15]. Similarly, the expression of
complement factor B, whose expression is increased by
pro-inflammatory cytokines, was decreased in MTX-
responsive patient samples. The decreased expression pat-
terns of chemokine receptor 6, granzymes A and K, and
the killer cell lectin like receptor subfamily D member 1
and subfamily K member 1 transcripts suggest modulation
by MTX in cells of the innate (natural killer cells) and
adaptive (cytotoxic T cells) immune systems in JIA. Input
of the differentially expressed genes from this analysis into
IPA software revealed a statistically significant downregu-
lation of leukocyte activation in samples from the metho-
trexate-responsive samples based on the downregulation
of five genes: GZMA, which activates monocytes [16],
STAT1 whose phosphorylation leads to macrophage acti-
vation [17], CALR, which increases activation of dendritic
cells [18], SERPINB9, which increases leukocyte activation
[19], and KLRK1, which increases NK cell activation [20].
Upregulation of CALR, PRDM1, STAT1, TAGAP and
TNRC6B has been associated elsewhere with adult rheu-
matoid arthritis or juvenile polyarticular arthritis [21-24].
Their downregulation here is consistent with an immuno-
suppressive effect of MTX across a variety of different
molecules. Downregulation of GZMA by MTX was pre-
viously reported by Belinsky et al. [25].
Fifty-two genes represented by 56 different probe sets
were differentially expressed in PBMC samples from
patients treated with MTX + Et relative to samples from
healthy controls (Table S2 in Additional file 2). Transcripts
for 25 of these genes were expressed in higher levels in
patients and 27 were expressed in lower levels compared
with controls. GO analysis indicated an overrepresentation
of products of the differentially expressed genes with roles
in immunity, as expected. Of the 24 GO biological process
categories obtained, 11 were related to immunity with
ratios of the number of observed to expected genes varying
from 4.57 to 22.05. The second-most overrepresented cate-
gories were related to histone or chromatin modification,
with observed/expected ratios between 3.29 and 12.53.
This finding is consistent with the hypothesis that altera-
tions in gene expression that characterize the transition
from active disease to remission may be accomplished
alterations in chromatin accessibility through epigenetic
alterations.
Twenty-one of the transcripts which showed differential
expression when the MTX + Et group was compared with
controls, including KLRD1 and CFB, were also differen-
tially expressed in the MTX alone group vs. controls, sug-
gesting either MTX-induced changes in the expression of
these genes or persistence of pre-existing expression
abnormalities not corrected by either drug regimen.
AGRN and KLRD1, which showed decreased expression in
the patient samples, are involved in T cell activation. CFB,
AGRN and KLRD1 are involved in inflammatory response,
while CFB and AGRN plus PPP1R14A are involved in cell-
cell interactions. The remaining 31 genes were uniquely
differentially expressed in the MTX + Et vs. controls com-
parison (including CD22, CCR6 and TREM1 which are of
immunologic interest and suggest a unique effect of Et or
MTX + Et interaction) and 46 that were uniquely differen-
tially expressed in the MTX vs. controls (including
CXCR6, GZMA, TCRGC2, TCRGV5, TCR delta and
STAT1, which are of immunologic interest and suggest
the unique effect of MTX). The increased expression of
CD22 and decreased expression of TREM1 which
occurred in patients who responded to the combined
methotrexate and etanercept therapy but not those who
responded to methotrexate alone suggests an Et-depen-
dent effect on these molecules. CD22 is known to nega-
tively regulate B cell activation [26,27], while TREM1
activation in monocytes induces pro-inflammatory cyto-
kines and chemokines such as TNF, IL-1 and IL-6 [28,29].
The transcriptional modulation of these molecules in
response to these therapies should reduce inflammation
and modulate immune responses in responding patients.
Differential expression of genes in granulocytes
The most striking differences in gene expression profiles of
patients with JIA responding to therapy were detected in
granulocytes. A total of 207 differentially expressed genes
were identified when samples from patients treated with
MTX + Et were compared to control samples (Table S3 in
Additional file 3). This contrasts with 23 genes that were
differentially expressed in patients who achieved remission
on MTX relative to controls (Table S4 in Additional file 4).
That is, patients achieving remission on MTX alone had
granulocyte gene expression profiles that more closely
resembled normal than patients treated with MTX + Et.
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Four genes were upregulated in samples from patients that
achieved remission with either therapeutic regimen, namely
chromodomain helicase DNA-binding protein 2 (CHD2),
RNA-binding motif protein 25 (RBM25), tripartite motif-
containing 23 (TRIM23) and the KIAA0907 gene; seven
genes were downregulated in both groups of patient
samples relative to controls, namely forkhead box O1
(FOXO1), 3-phosphoinositide-dependent protein kinase-1
(PDPK1), PHD finger protein 20 (PHF20), splicing factor,
arginine/serine-rich 18 (SFRS18), SAPS domain family,
member 3 (SAPS3), neutral sphingomyelinase activation
associated factor (NSMAF), and transmembrane protein
140 (TMEM140). FOXO proteins have been shown to reg-
ulate the expression of the TFN-related apoptosis-inducing
ligand (TRAIL) [30], a TNF family member that can accel-
erate the rate of apoptosis in neutrophils [31-33]. TNF has
been shown to induce granulocyte apoptosis in a dose-
dependent manner, and via differential effects on expres-
sion of Mcl-1 and Bfl-1 [34-36]. Twenty-eight statistically
significant (P <10-2) canonical pathways were identified
from the MTX + Et differentially expressed genes using
IPA, many of which are directly associated with inflamma-
tion, immunity, or apoptosis (Table 4). These include the
RANKL signaling pathway, which regulates bone remodel-
ing, the caspases-dependent apoptotic TWEAK signaling
pathway, the CD27 apoptotic signaling pathway, the
TNFR2 signaling pathway, the antigen-presenting CD40
signaling pathway, the TNF family and immunoregulatory
APRIL and BAFF signaling pathways, the glucocorticoid
receptor signaling pathway, and the IL-6 signaling pathway.
Many of these differentially expressed genes, such as ATM,
BIRC3, MAP2K7, NFKBIE, TRAF3 and XIAP, occurred in
more than one signaling pathway. Based on the expression
patterns of the molecules in Table 4 IPA software pre-
dicted decreased cellular apoptosis (3.24 × 10-4). Collec-
tively, these findings demonstrate an important role of Et
in the modulation of the innate immune system of
responding patients, which may have implications for this
and other diseases.
Between-group comparisons
Having established that CRM is not a return to normal,
we next sought to determine the degree to which the
homeostatic state induced by MTX alone resembled
that induced by the combination of MTX + Et.
We first examined PBMC, comparing the gene expres-
sion profiles in JIA patients in remission following treat-
ment with combined MTX + Et to samples from patients
treated with MTX alone. Six genes were identified as
being differentially expressed in PBMC between these
groups (Table S5 in Additional file 5). Four genes were
upregulated in patients treated with the combined therapy:
cardiotrophin-like cytokine factor 1 CLCF1 complement
component 3 (C3), nonprotein-encoding XIST antisense
RNA (TSIX), and one gene currently lacking annotation
(Affymetrix probe set ID 240861_at). Two genes were
downregulated in patients using combined therapy: insu-
lin-like growth factor 1 receptor (IGF1R) and the Y-linked
protein kinase gene (PRKY).
When the granulocyte expression profiles of children
who achieved remission on MTX were compared
directly with those who achieved remission on MTX +
Et, we found 33 genes (42 probes) that showed differ-
ences in expression. This was an expected finding, given
that children who had remission on MTX alone had
expression profiles that more closely resembled the
healthy controls than did children who achieved remis-
sion on MTX + Et.
Differential gene expression was also detected with
three different probes for the eukaryotic translation
initiation factor 1A, Y-linked gene (EIF1AY) with no evi-
dence of expression in the MTX + Et samples relative to
the MTX alone samples, with six different probes for the
nonprotein-coding × (inactive)-specific transcript (XIST)
with expression above background only in the MTX +
Et-treated samples, and with three different probes for
the nibrin gene (NBN) expressed above background sig-
nal intensities in both groups. Only one gene, the insulin-
like growth factor 1 receptor gene (IGF1R), was differen-
tially expressed in both PBMC and neutrophils. However,
this gene was overexpressed in granulocytes from
patients treated with MTX + Et, but underexpressed in
MTX + Et-treated PBMC samples. Collectively, these
findings indicate very different effects of Et on different
subsets of peripheral blood.
The nibrin gene was overexpressed in MTX + Et rela-
tive to both MTX only and controls, as were the genes
encoding for cytochrome b-245, beta polypeptide
(CYBB), haloacid dehalogenase-like hydrolase domain-
containing 1A (HDHD1A), baculoviral IAP repeat-con-
taining 3 (BIRC3), TNF receptor-associated factor 3
(TRAF3), and × (inactive)-specific transcript (XIST). The
histone cluster 1, H1c (HIST1H1C) gene was found to
be downregulated in MTX + Et relative to both MTX
only and control samples. No overlap was found among
the differentially expressed genes in the MTX only vs.
MTX + Et and the MTX only vs. control samples
(Table S6 in Additional file 6).
Network analysis of differentially expressed genes
Functional associations between differentially expressed
genes identified above were analyzed using the IPA soft-
ware. It is interesting to note that many of these networks
contained hub-and-node structures characteristic of scale-
free systems [37] as we have previously reported [38].
While some of these structures may be artifacts that
emerge from the algorithms used by IPA to query the
existing literature, there is biological coherence in many of
the networks, all of which were generated in an unbiased
fashion. For example, in both PBMC (Figure 1A, and
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Figure S1 in Additional file 7) and granulocytes (Figure 1B,
and Figure S2 in Additional file 8), TNF alpha appears as a
hub in at least one network, as would be predicted given
Et’s mechanism of action. We also noted hub-and-node
structured networks derived from both types of cells that
demonstrated interactions between the steroid hormone
receptor/transcription factor hepatocyte nuclear factor 4
alpha (HNF4a) and differentially expressed gene products
in both types of cells (Figure 2). Connections in these net-
works reflect HNF4a binding to DNA sequences in or
adjacent to these genes that were identified by chromatin
immunoprecipitation assays [39]. Because HNF4a had not
been reported to be expressed in leukocytes, we undertook
experiments to investigate this finding further.
Figure 1 Networks derived from Ingenuity Pathway Analysis software of children who achieved CRM status using MTX + Et compared
with healthy controls. Network analysis in PBMC is shown in (A) and analysis in granulocytes is shown in (B). Note prominence of TNFA as a
hub in these networks. Genes shown in red show higher expression in patients compared with controls, and those shown in green show lower
expression..CRM, clinical remission on medication; ET, etanercept; MTX, methotrexate; PBMC, peripheral blood mononuclear cells.
Figure 2 Network derived from Ingenuity Pathway Analysis software of children who achieved CRM status using MTX + Et (A) or MTX
alone (B) compared with healthy controls. Network analysis is from PBMC (A) and granulocytes (B). Note the prominence of HNF4a as a hub
in both networks. Genes shown in red show higher expression in patients compared with controls, and those shown in green show lower
expression. CRM, clinical remission on medication; ET, etanercept; MTX, methotrexate; PBMC, peripheral blood mononuclear cells.
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Expression of HNF4a in leukocytes
Network analyses of the microarray data suggested a
role for HNF4a in regulating a number of genes asso-
ciated with remission (for example, Figure 2). HNF4a is
a transcription factor and a steroid hormone receptor
superfamily member that is expressed mainly in liver
and kidney, and at lower levels in pancreatic islets, small
intestine and colon [40]. Given the relationship between
HNF4a and a number of the differentially expressed
genes in PBMC and granulocytes, we tested for the pre-
sence of HNF4a protein in human leukocytes using
immunofluorescence microscopy. As a positive control,
we observed intense nuclear and light cytoplasmic stain-
ing in human hepatocellular carcinoma HepG2 cells
(Figure 3A). We next examined CD66b+ granulocytes,
CD4+ T cells, and CD8+ T cells and detected HNF4a
in each of these leukocyte subsets. In T cells, HNF4a
immunofluorescent signals were of similar intensity in
CD8+ and in CD4+ T cells and lower than intensities
observed in CD66b+ granulocytes. All T cells were immu-
nofluorescent positive for HNF4a while one-third of
CD66b+ cells were positive. Staining in CD66b+ cells was
primarily cytoplasmic, while nuclear and cytoplasmic
staining was observed among each T cell subpopulation.
All of these findings were observed in cells from healthy
children, healthy adults, and children with JIA (data not
shown). The findings support the hypothesis that HNF4a
is expressed in each of these types of cells and indirectly
corroborate the functional interaction of gene products in
the networks reported above.
Validation of microarray data
We performed quantitative real-time PCR on RNA
obtained from granulocytes and PBMC from the training
cohort of patients and healthy controls to confirm the
altered pattern of gene expression detected with microar-
rays. Ten differentially expressed genes identified from
microarray expression patterns of PBMC were evaluated
(Figure 4A). All genes were similarly over- or under-
expressed using both methods. In granulocytes, nine
genes that were tested by qRT-PCR exhibited agreement
between microarray and quantitative real-time PCR
results (Figure 4C). To further confirm the findings from
the microarray results, 12 differentially expressed genes
identified from microarray expression patterns in PBMC
and 14 differentially expressed genes identified from
microarray expression patterns in granulocytes were eval-
uated by quantitative real-time PCR on RNA obtained
from the independent testing cohort. The PCR results
confirmed the differential expression of 11 of the 12
genes in PBMC (Figure 4B, 92% validation) and 13 of the
14 genes in granulocytes (Figure 4D, 93% validation). The
differentially expressed gene CXCR6 in PBMC and
FOXO1 in neutrophils were not been validated by PCR
(data not shown). Five (IER5, FUZ, RNF167, TRIM4 and
ZNF277) of the 13 genes we validated in granulocytes
were also relevant directly to the HNF4a network men-
tioned above. TARP, which was present in the PBMC
network with an HNF4A hub (above), was validated by
PCR in both training and testing groups. Thus, PCR
experiments, including those performed on an indepen-
dent patient cohort, corroborated results from both the
expression and network analysis data.
Discussion
Significant advances have been made in the past 10 to 15
years in the treatment of JIA. Indeed, it is now possible to
achieve remission in the majority of children with even
the more severe polyarticular-onset forms of this disease,
although sustained periods without clinical disease can
currently be achieved and maintained only by sustained
use of immunosuppressive medications. While preliminary
studies from our group suggested that remission (both
CRM and CR) in JIA represents a distinct biological ‘state’
that can be recognized at the molecular level as well as
clinically [6], it is critical to derive a deeper understanding
of the biological meaning of these states. In particular,
since children with JIA can achieve remission on different
medications, it is of great interest to know whether remis-
sion achieved on MTX leads to an identical immunologic/
biologic state as that achieved on a TNF inhibitor. We
demonstrate here that children who have achieved the
CRM state show significant differences from healthy con-
trols, although those differences are more pronounced in
the group who achieved remission on MTX + Et com-
pared with those who achieved remission on MTX alone.
The findings here corroborate our smaller, preliminary
studies [22] and demonstrate that the CRM state is not a
return to ‘normal’, but rather a re-ordering of transcrip-
tional profiles in leukocytes (and very possibly other cells
or tissues) in such a way that pro-inflammatory responses
are counterbalanced by anti-inflammatory responses.
Furthermore, this re-ordering occurs in cells of both the
innate and adaptive immune systems. Findings in this
study are thus consistent with previously published work
[5,6,22,40] suggesting that, rather than being driven purely
by aberrant adaptive immune processes, the pathogenesis
of polyarticular JIA likely involves complex interactions
between innate and adaptive immunity. For example, 21 of
the differentially expressed genes in PBMC in patients
(MTX + Et and MTX alone) relative to controls are
known to be involved in T cell activation (AGRN and
KLRD1), inflammation response (CFB, AGRN and
KLRD1), and cell-cell interaction (CFB, AGRN and
PPP1R14A). The differentially expressed genes in PBMC
in patients (MTX alone) relative to controls are involved
in T cell and NK cell proliferation (STAT1 and KLRK1)
and in T cell apoptosis and death (SERPINB9, CALR,
PRDM1 and GZMA).
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The more dramatic differences between children in
remission and healthy control children were observed in
the expression profiles of granulocytes. This was especially
true when we compared children in remission on MTX +
Et with the control population. In that comparison, there
were 207 genes that showed differential expression. Not
surprisingly, many of the differentially expressed genes act
through TNF-associated pathways. For example, ABCF1
can be regulated by TNF-alpha and play a role in enhance-
ment of protein synthesis and the inflammation process
[41]. TNFAIP6, increased in JIA patient granulocytes, can
be induced by pro-inflammatory cytokines such as TNF-
alpha and IL-1 [42]. Enhanced levels of TNFAIP6 protein
have also been found in the synovial fluid of patients with
osteoarthritis and rheumatoid arthritis [43]. GCH1 protein
expression and enzyme activity are strongly induced by a
mixture of three pro-inflammatory cytokines, IL-1beta,
TNF-alpha, and IFN-gamma [44]. XIAP belongs to a
family of apoptotic suppressor proteins and acts by bind-
ing to TNF receptor-associated factors TRAF1 and
TRAF2. This protein also inhibits at least two members of
the caspase family of cell-death proteases, caspase-3 and
caspase-7. XIAP also regulates innate immune responses
by interacting with NOD1 and NOD2 through interaction
with RIP2 [45,46].
Despite the large number of differentially expressed
genes in granulocytes of patients who responded to
MTX + Et therapy, only 23 differentially expressed
genes in granulocytes were identified in patients that
achieved remission on MTX relative to controls. This
Figure 3 Expression of HNF4a in leukocytes. Indirect immunofluorescence microscopy was used to detect the expression of HNF4a. Cells
were fixed in 4% paraformaldehyde and stained with antibodies against human CD4, CD8, CD66b, and HNF4a. (A) HepG2 cells as positive
control. (B) Granulocytes. (C and D) Peripheral blood mononuclear cells.
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finding argues that the majority of the MTX +Et tran-
scriptome changes were affected by Et. Nevertheless,
there may be functional overlap in genes affected by
these therapeutic regimens. For example, among genes
affected by MTX, neutral sphingomyelinase (N-SMase)
activation associated factor (NSMAF), downregulated in
MTX-treated patient vs. control samples, is an adaptor
protein that constitutively binds to TNF-R1 and is
involved in TNF-induced gene expression such as IL-6
and CXCL-2, and leukocyte recruitment, contributing to
the establishment of the specific immune response [47].
The effect of these drugs is not limited to TNF-related
modifications. Eleven genes (CHD2, KIAA0907, PHF20,
RBM25, NSMAF, FOXO1, PDPK1, SAPS3, SFRS18,
TMEM140 and TRIM23) were differentially expressed
following treatment with MTX or MTX + Et, and parti-
cipate in various cellular processes including cellular
development, carbohydrate metabolism, cell morphol-
ogy, cell death and gene expression.
A number of differentially expressed genes identified in
this study have been shown to bind the transcription fac-
tor HNF4a [40]. HNF4a belongs to the steroid hormone
receptor superfamily and is enriched in liver [48].
HNF4a contributes to regulation of a large fraction of
the liver and pancreatic islet transcriptomes by binding
directly to nearly half of the actively transcribed genes in
those tissues and plays a role in regulating the cytokine-
induced inflammatory response [41,49]. Based on the
predicted interaction between HNF4a and a number of
differentially expressed genes in this study, we demon-
strated expression of HNF4a in leukocytes at the protein
level in PBMC and granulocytes from patients with JIA
and from healthy controls using immunofluorescence
assays. HNF4A transcripts were expressed above back-
ground signal intensities on the microarrays (data not
shown). Our results support the hypothesis that HNF4a
controls many genes associated with remission. Although
we did not see significant differences in the expression
levels of HNF4A transcripts in leukocytes between
patients and healthy controls, HNF4a may be controlled
by posttranscriptional events or may act as a cofactor,
interacting with other transcription factors, for example
ETS-domain transcription factor ELK1, and not directly
bind to DNA to regulate these genes [50]. Some ETS
family proteins interact with other transcription factors
(AP-1, NF-B and Stat-5) to co-regulate the expression
of cell-type-specific genes, and these interactions coordi-
nate cellular processes in response to diverse signals
Figure 4 Validation of microarray data for selected genes by real-time PCR. (A and B) Differentially expressed genes in PBMC from JIA
patients who achieved remission using MTX alone or MTX + Et were compared to healthy controls in training cohort (A) and testing cohort (B).
(C and D) Differentially expressed genes in granulocytes from JIA patients who achieved remission using MTX alone or MTX + Et were
compared to healthy controls in training cohort (C) and testing cohort (D). ET, etanercept; JIA, juvenile idiopathic arthritis; MTX, methotrexate;
PBMC, peripheral blood mononuclear cells.
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from cytokines, growth factors, antigens, and cellular
stresses [51]. The differences in the intracellular localiza-
tion of HNF4a observed here in granulocytes and T cells
remain to be explained. They may be related to the abun-
dance of other transcriptional binding factors in such
cells or to mutations or exon splice variations that are
present in the HNF4A gene.
Together, our results demonstrate that the remission
state in JIA is not the result of a normalization of
immune homeostasis. Gene expression in both PBMC
and granulocytes remains abnormal when patients in
remission are compared with healthy control children.
Furthermore, while there are some overlapping points,
remission achieved on MTX differs from remission
achieved on MTX + Et, especially in granulocytes, sug-
gesting overlapping but not identical ‘set points’ for
each of these remission states.
These findings provide insight into one of the single
most important clinical features of chronic arthritis in
children: the frequency of disease recurrence and the rar-
ity of true remission (defined by the Wallace group as a
full year off all medications without recurrence of disease
signs or symptoms). Our studies show that the CRM state
is still associated with distinct differences between chil-
dren in remission (who appear to be completely normal)
and perfectly healthy children. The degree to which these
abnormalities reflect persistence of the underlying condi-
tion itself or a new immunologic homeostasis that
emerges because of the drugs themselves is unclear,
although our earlier studies [5,6] strongly suggest the lat-
ter. Longitudinal studies will be required to monitor the
expression of these or other genes prior to, throughout,
and after treatment to identify biomarkers that may pre-
dict which patients with JIA are likely to respond to parti-
cular therapeutic regimens to optimize therapy in the
future. These findings represent the first steps in the
identification of such molecules.
Conclusions
Remission (CRM) in polyarticular JIA is a distinct biologi-
cal state that differs from normal. Gene expression profiles
of PBMC show little differences whether the CRM state
was achieved with MTX or the combination of MTX + Et.
However, the CRM state in JIA neutrophils show signifi-
cant differences depending on whether remission was
achieved with MTX or MTX + Et. These findings there-
fore add evidence to the importance of neutrophils in the
pathogenesis of JIA and its response to therapy.
Additional material
Additional file 1: Table S1. Differentially expressed genes in PBMC in
JIA patients who achieved remission with methotrexate alone vs.
controls. Genes listed more than once indicate different probes for the
same gene which showed different values in expression.
Additional file 2: Table S2. Differentially expressed genes in PBMC in
JIA patients who achieved remission with etanercept and methotrexate
vs. controls. Genes listed more than once indicate different probes for
the same gene which showed different values in expression.
Additional file 3: Table S3. Differentially expressed genes in
granulocytes of JIA patients who achieved remission with methotrexate
and etanercept vs. controls. Genes listed more than once indicate
different probes for the same gene which showed different values in
expression.
Additional file 4: Table S4. Differentially expressed genes in
granulocytes of JIA patients who achieved remission with methotrexate
alone vs. controls. Genes listed more than once indicate different probes
for the same gene which showed different values in expression.
Additional file 5: Table S5. Differentially expressed genes in PBMC in
JIA patients who achieved remission with methotrexate and etanercept
vs. methotrexate alone.
Additional file 6: Table S6. Differentially expressed genes in
granulocytes in JIA patients who achieved remission with methotrexate
and etanercept vs. methotrexate alone. Genes listed more than once
indicate different probes for the same gene which showed different
values in expression.
Additional file 7: Figure S1. Interactions between products of
differentially expressed genes in PBMC from patients with JIA who
achieved remission using methotrexate alone (A) or Etanercept and
Methotrexate (B) relative to PBMC from controls. Differentially expressed
genes entered in the Ingenuity Pathway Analysis program are colored.
Genes shown in red show higher expression in patients compared with
controls, and those shown in green show lower expression. Genes not
colored were added by the IPA program to generate these networks.
Additional file 8: Figure S2. Interactions between products of
differentially expressed genes in granulocytes from patients with JIA who
achieved remission using methotrexate alone (A) or Etanercept and
Methotrexate (B) relative to granulocytes from controls. Differentially
expressed genes entered in the Ingenuity Pathway Analysis program are
colored. Genes shown in red show higher expression in patients
compared with controls, and those shown in green show lower
expression. Genes not colored were added by the IPA program to
generate these networks.
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